Next Article in Journal
Cell-Penetrating Penta-Peptides (CPP5s): Measurement of Cell Entry and Protein-Transduction Activity
Next Article in Special Issue
Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials
Previous Article in Journal
Effects of Moxifloxacin on Human Neutrophil and T-Lymphocyte Functions in Vitro
Previous Article in Special Issue
Artesunate: The Best Drug in the Treatment of Severe and Complicated Malaria
Pharmaceuticals 2010, 3(12), 3581-3593; doi:10.3390/ph3123581
Review

Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress

1,*  and 2
1 Centre for Health Research, Divine Word University, P O Box 483, Madang 555, Madang Province, Papua New Guinea 2 Medical Research Institute, Kunming Pharma, West suburb, Xishan Region, Kunming, China
* Author to whom correspondence should be addressed.
Received: 15 November 2010 / Revised: 8 December 2010 / Accepted: 9 December 2010 / Published: 14 December 2010
(This article belongs to the Special Issue New Antimalarial Drugs)
View Full-Text   |   Download PDF [205 KB, uploaded 14 December 2010]   |  

Abstract

With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO® is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO® is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin-naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin-naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO® the next generation ACT for the treatment of uncomplicated falciparum malaria.
Keywords: artemisinin-naphthoquine combination; ARCO; artemisinin; naphthoquine; Plasmodium falciparum artemisinin-naphthoquine combination; ARCO; artemisinin; naphthoquine; Plasmodium falciparum
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Hombhanje, F.W.; Huang, Q. Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress. Pharmaceuticals 2010, 3, 3581-3593.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert